Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose

NCT01125527 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01125527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01125527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2009
Completion date
April 30, 2010
Enrollment
700 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilus influenzae type b (hib) infection